Consensus Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2026-09-11 pm EDT			5-day change	1st Jan Change
55.41 ^USD	-0.47%		+0.14%	+25.79%

Sep. 11	Scholar Rock Receives FDA Approval For ISEMBYLD Apitegromab-Mstn For Treatment Of Spinal Muscular Atrophy	CI
Sep. 11	Scholar Rock gets first FDA nod for rare muscle-wasting disease	RE

Evolution of the Average Target: Scholar Rock Holding Corporation

Evolution of the Target Price: Scholar Rock Holding Corporation

Changes in Analyst Recommendations: Scholar Rock Holding Corporation

a6fcb9fa7530f362e0b8665.tpxsyOtBwQ7UN2LgOIcNeIQFGQCDxwAPUxBandPjAWo.x8NV_I0LqEGebVSBfdBqEN0wa3bh8FR5ZEUc-4a2Q1-Fzz2evGygee1jMw~4809bca3520f07f8eaac7a0ce0df3c9a

Analysts' recommendations: Scholar Rock Holding Corporation

Aug. 21	Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating	MT
Apr. 21	Canaccord Genuity Initiates Scholar Rock at Buy With $62 Price Target	MT
Mar. 31	Wedbush Adjusts Price Target on Scholar Rock Holding to $58 From $56, Maintains Outperform Rating	MT
Mar. 04	Truist Raises Price Target on Scholar Rock Holding to $55 From $44, Keeps Buy Rating	MT
Mar. 03	Wedbush Adjusts Price Target on Scholar Rock to $56 From $50, Maintains Outperform Rating	MT
Jan. 07	UBS Initiates Scholar Rock Holding at Buy With $60 Price Target	MT
Nov. 14	Wedbush Adjusts Pt on Scholar Rock Holding to $50 From $43, Maintains Outperform Rating	MT
25-09-23	HC Wainwright Adjusts Price Target on Scholar Rock Holding to $44 From $50, Maintains Buy Rating	MT
25-09-23	Scholar Rock's Apitegromab Approval Still Likely Despite Delay, Wedbush Says	MT
25-09-17	Barclays Initiates Scholar Rock at Overweight With $45 Price Target	MT
25-09-15	Leerink Partners Initiates Scholar Rock at Outperform With $51 Price Target	MT
25-08-06	Biopharma Scholar Rock Q2 net loss widens, no revenue	RE
25-07-18	Truist Raises Price Target on Scholar Rock Holding to $54 From $45, Keeps Buy Rating	MT
25-07-17	Cantor Fitzgerald Initiates Coverage on Scholar Rock With Overweight Rating	MT
25-02-27	Wedbush Adjusts Scholar Rock Price Target to $50 From $47, Maintains Outperform Rating	MT
24-11-25	Wedbush Raises Price Target on Scholar Rock to $47 From $40, Maintains Outperform Rating	MT
24-11-25	Truist Securities Adjusts Price Target on Scholar Rock to $45 From $36, Maintains Buy Rating	MT
24-11-12	Wedbush Raises Price Target on Scholar Rock to $40 From $37, Maintains Outperform Rating	MT
24-10-08	Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says	MT
24-10-07	Scholar Rock's Phase 3 Apitegromab Trial in Spinal Muscular Atrophy Meets Primary Endpoint	MT
24-10-07	Wedbush Raises Price Target on Scholar Rock Holding to $27 From $25, Keeps Outperform Rating	MT
24-10-07	Truist Raises Price Target on Scholar Rock Holding to $36 From $20, Keeps Buy Rating	MT
24-09-27	Wedbush Raises Price Target on Scholar Rock to $25 From $23, Keeps Outperform Rating	MT
24-06-13	BMO Capital Raises Price Target on Scholar Rock to $31 From $29, Maintains Outperform Rating	MT
24-03-28	Raymond James Initiates Scholar Rock With Strong Buy Rating, $30 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SCHOLAR ROCK HOLDING CORPORATION					+9.64%
	WUXI APPTEC CO., LTD.					+23.69%
	ARGENX SE					+18.14%
	INSMED INCORPORATED					+54.69%
	WUXI BIOLOGICS (CAYMAN) INC.					+23.66%
	BIONTECH SE					+23.2%
	GENMAB A/S					+17.29%
	PHARMAESSENTIA CORPORATION					+9.16%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+32.94%
	EXELIXIS, INC.					-4.33%
	Average					+20.81%
	Weighted average by Cap.					+22.96%